司美拉诺肽治疗获得性下丘脑性肥胖:一项2期、开放标签、多中心试验
这项2期开放标签多中心试验在美国5个中心纳入18例下丘脑损伤相关肥胖患者,每日皮下注射司美拉诺肽滴定至3.0 mg,治疗16周。16例(89%)患者BMI较基线降低至少5%(p<0.0001),全部患者BMI平均降低15%(SD 10)。常见不良事件包括恶心(61%)、呕吐(33%)、皮肤色素沉着(33%)和腹泻(22%)。
要点
- 16周时89%(16/18)患者BMI较基线降低至少5%,达到主要终点(p<0.0001)。
- 全部患者BMI平均降低15%(SD 10),12岁及以上患者饥饿评分平均降低45%。
- 常见不良事件为恶心(61%)、呕吐(33%)、皮肤色素沉着(33%)和腹泻(22%)。
核心结论
- 这些发现支持司美拉诺肽作为下丘脑性肥胖的一种新型有效治疗方法。
研究设计与样本
- 2期、开放标签、多中心试验,在美国5个中心进行。
- 纳入年龄6至40岁、有下丘脑损伤史或接受过手术、化疗或放疗的非恶性肿瘤影响下丘脑的患者,共18例接受至少一剂司美拉诺肽。
- 司美拉诺肽滴定至3.0 mg,每日皮下注射一次,总疗程16周。
- 主要终点为16周后BMI较基线降低至少5%的患者比例,与历史对照率低于5%比较;主要终点采用全分析集分析。
- 试验注册号ClinicalTrials.gov NCT04725240,已完成。
主要发现
- 2021年6月6日至2022年1月13日筛查19例,排除1例,18例入组并接受至少一剂司美拉诺肽。
- 患者主要为白人(14例[78%])和男性(11例[61%]),平均年龄15.0岁(SD 5.3),平均BMI 38.0 kg/m2(SD 6.5)。
- 18例中16例(89%)完成研究并达到主要终点,即16周后BMI较基线降低至少5%(p<0.0001)。
- 全部患者BMI平均降低15%(SD 10);复合临床有意义变化比例为89%(90% CI 69-98%;p<0.0001),其中18岁以下患者BMI Z评分降低至少0.2点的比例为92%(68-100%;p<0.0001),18岁及以上患者体重降低至少5%的比例为80%(34-99%;p<0.0001)。
- 12岁及以上患者饥饿评分平均降低45%;常见不良事件包括恶心(61%)、呕吐(33%)、皮肤色素沉着(33%)和腹泻(22%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. METHODS: This phase 2, open-label, multicentre trial was done in five centres in the USA. Eligible patients were aged between 6 and 40 years with obesity and history of hypothalamic injury or diagnosis of a non-malignant tumour affecting the hypothalamus that was treated with surgery, chemotherapy, or radiation. Setmelanotide was titrated up to a dose of 3·0 mg and administered subcutaneously once a day for a total duration of 16 weeks. The primary endpoint was the proportion of patients with a reduction in BMI of at least 5% from baseline after 16 weeks, compared with a historic control rate of less than 5% in this population. The primary endpoint was analysed using the full analysis set, which includes all patients with baseline data who received at least one dose of setmelanotide. Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT04725240) and is complete. FINDINGS: Between June 6, 2021, and Jan 13, 2022, 19 patients were screened for inclusion. One patient was excluded, and 18 were enrolled and received at least one dose of setmelanotide. Patients were primarily White (n=14 [78%]) and male (n=11 [61%]). Enrolled patients had a mean age of 15·0 years (SD 5·3) and a mean BMI of 38·0 kg/m2 (SD 6·5). Of 18 patients enrolled, 16 (89%) of 18 patients completed the study and met the primary endpoint of reduction in BMI of at least 5% from baseline after 16 weeks (p<0·0001). The mean reduction in BMI across all patients was 15% (SD 10). A composite proportion of patients had a clinically meaningful change (89%, 90% CI 69-98%; p<0·0001), comprising a reduction in BMI Z score of at least 0·2 points for patients younger than 18 years (92%, 68-100%; p<0·0001) and reduction in bodyweight of at least 5% for patients aged 18 years or older (80%, 34-99%; p<0·0001). Patients aged 12 years or older had a mean reduction in hunger score of 45%. Frequent adverse events included nausea (61%), vomiting (33%), skin hyperpigmentation (33%), and diarrhoea (22%). Of 14 patients who continued treatment in a long-term extension study (NCT03651765), 12 completed at least 12 months of treatment at the time of publication and had a mean change in BMI of -26% (SD 12) from index trial baseline. INTERPRETATION: These findings support setmelanotide as a novel effective treatment of hypothalamic obesity. FUNDING: Rhythm Pharmaceuticals.
引用
- Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024. PMID: 38697184. doi:10.1016/S2213-8587(24)00087-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。